Puma Biotech (PBYI) Tops Q2 EPS by 16c

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $56.5 million versus the consensus estimate of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Molson Coors Brewing (TAP) dropped from S&P 500